NASDAQ: GCTKGlucotrack Inc Stock
$5.15-0.58 (-10.12%)
Updated Dec 15, 2025
GCTK Price
$5.15
Fair Value Price
$14.39
Market Cap
$4.69M
52 Week Low
$4.22
52 Week High
$468.00
P/E
0x
P/B
1.7x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$25.85M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.01
Operating Cash Flow
-$15M
Beta
4.32
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GCTK Overview
GlucoTrack, Inc., a medical device company, develops non-invasive glucose monitoring devices for people suffering from diabetes and pre-diabetics. Known as Integrity Applications, Inc. until 2021/11, GlucoTrack was founded in 2001 and is based in Or Yehuda, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GCTK's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
GCTK
Ranked#40 of 46
Ranked#40 of 46
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $4.86 | A | |
| $9.24 | A | |
| $22.06 | A |
Be the first to know about important GCTK news, forecast changes, insider trades & much more!
GCTK News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GCTK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GCTK ($5.15) is undervalued by 64.23% relative to our estimate of its Fair Value price of $14.39 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GCTK ($5.15) is significantly undervalued by 64.23% relative to our estimate of its Fair Value price of $14.39 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
GCTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GCTK due diligence checks available for Premium users.
Valuation
GCTK fair value
Fair Value of GCTK stock based on Discounted Cash Flow (DCF)
Price
$5.15
Fair Value
$14.39
Undervalued by
64.20%
GCTK ($5.15) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GCTK ($5.15) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GCTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GCTK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
220.51x
Market
45.07x
GCTK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.7x
Industry
3.76x
GCTK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GCTK's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.2M
Profit Margin
0%
GCTK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.3M
Liabilities
$5.5M
Debt to equity
2.01
GCTK's short-term assets ($8.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GCTK's short-term assets ($8.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GCTK's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GCTK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
-$67.0k
Financing
$3.0M
GCTK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GCTK vs Medical Stocks
Glucotrack Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.